Last reviewed · How we verify
Anastrozole Tablets
Anastrozole Tablets is a Aromatase inhibitor Small molecule drug developed by Tolmar Inc.. It is currently FDA-approved for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women, Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer.
Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer.
Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer. Used for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women, Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer.
At a glance
| Generic name | Anastrozole Tablets |
|---|---|
| Sponsor | Tolmar Inc. |
| Drug class | Aromatase inhibitor |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Anastrozole is a non-steroidal aromatase inhibitor that selectively blocks aromatase, the key enzyme responsible for estrogen synthesis in postmenopausal women. By reducing estrogen levels, it deprives estrogen receptor-positive breast cancer cells of the hormone signals needed for growth and proliferation. This mechanism is particularly effective in hormone-dependent breast cancers where estrogen drives tumor progression.
Approved indications
- Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women
- First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women
- Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Headache
- Vaginal dryness
- Osteoporosis/bone loss
- Elevated cholesterol
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (PHASE3)
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (PHASE2)
- A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery (NA)
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer (PHASE3)
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anastrozole Tablets CI brief — competitive landscape report
- Anastrozole Tablets updates RSS · CI watch RSS
- Tolmar Inc. portfolio CI
Frequently asked questions about Anastrozole Tablets
What is Anastrozole Tablets?
How does Anastrozole Tablets work?
What is Anastrozole Tablets used for?
Who makes Anastrozole Tablets?
What drug class is Anastrozole Tablets in?
What development phase is Anastrozole Tablets in?
What are the side effects of Anastrozole Tablets?
What does Anastrozole Tablets target?
Related
- Drug class: All Aromatase inhibitor drugs
- Target: All drugs targeting Aromatase (CYP19A1)
- Manufacturer: Tolmar Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women
- Indication: Drugs for First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women
- Indication: Drugs for Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing